ClinicalTrials.gg
RecruitingNCT06572241Updated Apr 1, 2026

Quality of Labour Epidural Analgesia With Intrathecal Morphine as a Component of Combined Spinal Epidural

An interventional study of Intrathecal morphine and Saline solution (placebo) in Labor Pain, sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Labor Pain by Samuel Lunenfeld Research Institute, Mount Sinai Hospital — 3 open to participants now, 3 under way, none of them phase 3. Labor Pain · Samuel Lunenfeld Research Institute, Mount Sinai Hospital.

Planned enrollment
3rd of 15
182 · median 40
Started
2024
with 1 other
No phase
15 of 22
3 open now
Registered
20th of 22
by date

Among the 22 studies in Labor Pain by Samuel Lunenfeld Research Institute, Mount Sinai Hospital, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 15 with no phase, and was the 20th registered.

Labor Pain

426 studies on the registry are indexed under Labor Pain; 76 are open to participants now.

Browse Labor Pain studies →

Open to participants now

3 of the 22 studies in Labor Pain by Samuel Lunenfeld Research Institute, Mount Sinai Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 31 Labor Pain studies recruiting now, 8 (26%) set no upper age limit and 23 (74%) stop at 75 or younger; 3 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Labor Pain by Samuel Lunenfeld Research Institute, Mount Sinai Hospital, or all of them as a file.
02

Study summary

Neuraxial analgesia has shown to be the gold standard for effective labor pain relief, offering numerous benefits including enhanced pain control and maternal satisfaction. The methods to achieve neuraxial analgesia include lumbar epidural (LE), and combined spinal epidural (CSE). While LE may not consistently provide optimal pain relief, leading to frequent maternal requests for supplemental analgesics, CSE presents a promising advancement. This is due to the rapid onset of pain relief from intrathecal components, complemented by the longer-lasting effects of epidural medications. Intrathecal drugs have demonstrated the ability to offer more symmetrical blockades compared to epidurally administered medications. Nonetheless, some clinicians remain cautious about CSE due to the potential for increased pain when transitioning from spinal to less effective epidural analgesia. Long-acting opioids like morphine in the intrathecal space may mitigate this problem by providing transitional analgesia to the laboring parturient.

The primary aim of this randomized controlled trial is to provide evidence of whether the addition of 100 mcg of morphine in the intrathecal (spinal) component of CSE reduces the rate of breakthrough pain during labor.

Read the detailed description

The addition of morphine to a combination of bupivacaine and lipophilic opioids (fentanyl) for the spinal component of CSE for labor analgesia has been shown to increase the duration of analgesia. A meta-analysis by Al-Kazwini and coworkers suggests a possible beneficial prolonging effect of adding morphine to spinal analgesia, however, the authors concluded that more adequately powered randomized controlled trials (RCTs) are required to determine the benefits and harms of intrathecal morphine (ITM).

This prolonged duration of action of ITM may reduce the need for frequent top-ups, which could alleviate nursing and anesthesiologist workload and enhance maternal satisfaction. An RCT conducted by Vasudevan and coworkers has concluded that the addition of 100 mcg ITM along with bupivacaine and fentanyl reduced the incidence of breakthrough pain in labor. Another dose-finding study comparing 50 and 100 mcg of ITM as a component of CSE labor analgesia concluded that 100 mcg of ITM significantly lowers the local anesthetic consumption and shorter duration of the first stage of labor without any significant difference in adverse effects. The RCT by Vasudevan et al. had a small sample size, enrolled mixed parity patients, and utilized continuous infusion for labor analgesia maintenance.

Hence, the investigators plan to conduct adequately powered RCT enrolling only primigravidae patients, which tend to have more prolonged labor than multiparous and programmed intermittent epidural bolus (PIEB) with patient-controlled epidural analgesia (PCEA) will be used, which is a more contemporary labor maintenance technique.

03

Conditions studied

  • Labor Pain

Browse trials for

Keywords

  • combined spinal epidural
  • CSE
  • intrathecal morphine
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (≥18 years) term primiparous (≥37 weeks) patients with live singleton pregnancy
  • Patients who request labour analgesia and do not have any for neuraxial analgesia.
  • Less than or equal to 6 cm cervical dilation during the last vaginal examination.

Exclusion criteria

Exclusion Criteria:

  • Patients who are expected to be discharged within 24 hours of delivery.
  • Patients with chronic pain conditions, opioid use disorder, pre-gestational diabetes, obstructive sleep apnea, morbid obesity ( >40 kg/m2), or fetal abnormalities.
  • Patients who have intramuscular morphine within 12 hours or fentanyl >200 mcg in the preceding 4 hours.
  • Participants will be excluded from further analysis in case of spinal analgesic failure
  • Participants will be excluded from further analysis if labour lasts less than 2 hours
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
182 participants (estimated)

Study arms

  • Active comparator
    Morphine

    0.6 ml of 0.25% bupivacaine, fentanyl 10 mcg with morphine 100 mcg (total volume 1 ml) as intrathecal component of combined spinal epidural (CSE).

    Drug: Intrathecal morphine

  • Placebo comparator
    Placebo

    0.6 ml of 0.25% bupivacaine, fentanyl 10 mcg with normal saline 0.2 ml (total volume 1 ml) as intrathecal component of combined spinal epidural (CSE).

    Other: Saline solution (placebo)

Interventions

  • DrugMorphineStudies of MorphineMorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    morphine 100 mcg, included in the intrathecal component of combined spinal epidural (CSE).

    Also known as: Morphine

  • OtherSaline solution (placebo)

    normal saline 0.2 ml added to the intrathecal component of combined spinal epidural (CSE).

    Also known as: saline

06

What researchers measure

Primary outcomes

  1. Presence of breakthrough pain: questionnaire

    The rate of breakthrough pain is defined as the ratio of the number of episodes of breakthrough pain during labour analgesia and the duration of epidural analgesia. An episode of breakthrough pain during labour analgesia was defined as subjective discomfort due to pain or pressure increasing during a contraction (rated as NRS ≥3/10), which was successfully treated with the manual administration of supplemental medications.

    Time frame: 24 hours

Secondary outcomes

  1. Time to first episode of breakthrough pain in minutes

    The amount of time in minutes to the first recorded episode of breakthrough pain, defined as subjective discomfort due to pain or pressure increasing during a contraction (rated as NRS ≥3/10), which was successfully treated with the manual administration of supplemental medications.

    Time frame: 24 hours

  2. Epidural medication consumption (milliliters)

    The overall consumption of epidural medication throughout labour, in milliliters.

    Time frame: 24 hours

  3. Epidural pump settings: questionnaire

    Any adjustments made to the programmed intermittent bolus settings of the epidural pump will be recorded.

    Time frame: 24 hours

  4. Presence of fetal heart rate anomalies: questionnaire

    The presence of any fetal heart rate anomalies will be recorded

    Time frame: 24 hours

  5. Presence of Cesarean delivery: questionnaire

    The presence of Cesarean delivery will be recorded

    Time frame: 24 hours

  6. Analgesic consumption post-delivery: questionnaire

    Presence of analgesic consumption post-delivery will be recorded.

    Time frame: 24 hours

  7. Presence of pruritis: questionnaire

    The presence of pruritis (yes or no) will be recorded.

    Time frame: 24 hours

  8. Presence of nausea: questionnaire

    The presence of nausea(yes or no) will be recorded.

    Time frame: 24 hours

  9. Presence of vomiting: questionnaire

    The presence of vomiting(yes or no) will be recorded.

    Time frame: 24 hours

  10. Presence of sedation: questionnaire

    The presence of sedation(yes or no) will be recorded.

    Time frame: 24 hours

  11. Presence of respiratory depression: questionnaire

    The presence of respiratory depression(yes or no) will be recorded.

    Time frame: 24 hours

  12. Apgar score at 1 minute

    Apgar score recorded by the respiratory therapist, nurse or midwife at 1 minute of life.

    Time frame: 1 minute

  13. Apgar score at 5 minutes

    Apgar score recorded by the respiratory therapist, nurse or midwife at 5 minutes of life.

    Time frame: 5 minutes

  14. Umbilical artery pH

    Lab results for umbilical artery pH

    Time frame: 24 hours

  15. Umbilical vein pH

    Lab results for umbilical vein pH

    Time frame: 24 hours

  16. Satisfaction: questionnaire

    Post-delivery, patients will be asked how satisfied they were with their labour analgesia from 0-10, where 0 is no pain and 10 is the worst pain imaginable.

    Time frame: 24 hours

  17. Obstetric Quality of Recovery-10 (ObsQoR-10) score 24 hours

    ObsQoR-10 score at 24 hours. There are 10 questions, and the results are tabulated out of 100. The higher the overall score out of 100, the better quality of recovery a patient is experiencing.

    Time frame: 24 hours

07

Study locations

1 of 1 sites recruiting
  • Mount Sinai Hospital
    Toronto, Ontario M5G1X5, Canada
    Recruiting
    • Naveed Siddiqui, MD · Contactnaveed.siddiqui@uhn.ca · 416-586-5270
    • Ronald George, MD · Sub investigator
    • Narinder Singh, MD · Sub investigator
    • Afsheen Nasir, MD · Sub investigator
    • Kristi Downey, MSc · Sub investigator
    • Binu Jacob, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.

Of 192 non-industry interventional studies with no phase under Labor Pain, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 25 months is above that.

Counting every sponsor, half of 194 studies reached it within 9 months; a quarter within 5 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2024
First posted
Aug 27, 2024
StartActual
Nov 20, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06572241
Responsible party
Sponsor
First posted
Aug 27, 2024
Start date
Nov 20, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 1, 2026

Study contacts

Naveed Siddiqui, MD
Contact
naveed.siddiqui@uhn.ca
416-586-5270
Naveed Siddiqui, MD
principal investigator · MOUNT SINAI HOSPITAL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Morphine

Start the discussion